Business
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2025--Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":10600,"height":1888,"url":"https://media.zenfs.com/en/business-wire.com/d8ab4a1d31c02faa211f0f997b59061a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lPB_sKXCIqZUrgNr5qsBKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d8ab4a1d31c02faa211f0f997b59061a","width":960,"height":171},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aaH5wT8W2fGmyDE3b41Dhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d8ab4a1d31c02faa211f0f997b59061a","width":1200,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the phase 2 part of REJOICE-Ovarian01","length":158,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Phase 3 part of REJOICE-Ovarian01 to evaluate 5.6 mg/kg dose of raludotatug deruxtecan versus investigator’s choice of chemotherapy","length":131,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":289,"olType":false},{"type":"text","content":"BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2025--(BUSINESS WIRE)--Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.","length":515,"tagName":"p"},{"type":"text","content":"Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.","length":289,"tagName":"p"},{"type":"text","content":"The median overall survival for advanced ovarian cancer following recurrence can be as little as two years, with a five-year survival rate of 31.8% for those with distant s...